Published in AAPS J on September 16, 2014
Pilot Study of a Breast Cancer Vaccine Plus Poly-ICLC for Breast Cancer (Breast 41) | NCT01532960
Multi-peptide Vaccine With Basilixumab for Breast Cancer | NCT01660529
Gene Therapy in Treating Women With Metastatic Breast Cancer | NCT00849459
Nanoparticle Drug Delivery Systems Designed to Improve Cancer Vaccines and Immunotherapy. Vaccines (Basel) (2015) 0.91
Whole Tumor Antigen Vaccines: Where Are We? Vaccines (Basel) (2015) 0.87
Improving the clinical impact of biomaterials in cancer immunotherapy. Oncotarget (2016) 0.83
Surface-modified particles loaded with CaMKII inhibitor protect cardiac cells against mitochondrial injury. Int J Pharm (2017) 0.75
Nanoparticles in vaccine delivery. AAPS J (2015) 0.75
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99
Pathogen recognition and innate immunity. Cell (2006) 44.14
Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med (2010) 29.75
Breast cancer metastasis: markers and models. Nat Rev Cancer (2005) 9.93
Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res (1992) 9.02
Breast cancer statistics, 2013. CA Cancer J Clin (2013) 7.35
Cancer immunotherapy comes of age. J Clin Oncol (2011) 5.87
Toll-dependent selection of microbial antigens for presentation by dendritic cells. Nature (2006) 5.54
Chemokines enhance immunity by guiding naive CD8+ T cells to sites of CD4+ T cell-dendritic cell interaction. Nature (2006) 5.19
Spectral compensation for flow cytometry: visualization artifacts, limitations, and caveats. Cytometry (2001) 5.08
Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol (2007) 3.93
Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma. J Immunol (2005) 3.73
CD8+ T cell efficacy in vaccination and disease. Nat Med (2008) 3.20
To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J Control Release (2010) 3.06
Nanoparticles target distinct dendritic cell populations according to their size. Eur J Immunol (2008) 2.97
Antigen spreading contributes to MAGE vaccination-induced regression of melanoma metastases. Cancer Res (2011) 2.63
Mouse 4T1 breast tumor model. Curr Protoc Immunol (2001) 2.46
Enhanced and prolonged cross-presentation following endosomal escape of exogenous antigens encapsulated in biodegradable nanoparticles. Immunology (2006) 1.92
Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma. Clin Cancer Res (2003) 1.83
Analysis of the role of vaccine adjuvants in modulating dendritic cell activation and antigen presentation in vitro. Vaccine (2003) 1.73
Tumor-induced CD11b+Gr-1+ myeloid cells suppress T cell sensitization in tumor-draining lymph nodes. J Immunol (2008) 1.69
Using 3 TLR ligands as a combination adjuvant induces qualitative changes in T cell responses needed for antiviral protection in mice. J Clin Invest (2010) 1.58
Antigens for cancer immunotherapy. Semin Immunol (2008) 1.46
Effect of low dose cyclophosphamide on the immune system of cancer patients: depletion of CD4+, 2H4+ suppressor-inducer T-cells. Cancer Res (1988) 1.32
T-cell tolerance: central and peripheral. Cold Spring Harb Perspect Biol (2012) 1.28
Accumulation of foxp3+ T regulatory cells in draining lymph nodes correlates with disease progression and immune suppression in colorectal cancer patients. Clin Cancer Res (2010) 1.22
Autoimmunity associated with immunotherapy of cancer. Blood (2011) 1.22
Exploiting cross-priming to generate protective CD8 T-cell immunity rapidly. Proc Natl Acad Sci U S A (2010) 1.21
Polymeric particles in vaccine delivery. Curr Opin Microbiol (2010) 1.11
Biodegradable particles as vaccine delivery systems: size matters. AAPS J (2012) 1.09
Poly(lactic-co-glycolic acid) enhances maturation of human monocyte-derived dendritic cells. J Biomed Mater Res A (2004) 1.05
Type I IFNs control antigen retention and survival of CD8α(+) dendritic cells after uptake of tumor apoptotic cells leading to cross-priming. J Immunol (2011) 1.04
Past, present, and future challenges in breast cancer treatment. J Clin Oncol (2014) 1.04
Dendritic cell migration through the lymphatic vasculature to lymph nodes. Adv Immunol (2013) 1.03
Polymer nanoparticles containing tumor lysates as antigen delivery vehicles for dendritic cell-based antitumor immunotherapy. Nanomedicine (2010) 0.90
Inhibition of transforming growth factor-beta-mediated immunosuppression in tumor-draining lymph nodes augments antitumor responses by various immunologic cell types. Cancer Res (2009) 0.88
Enhanced stimulation of anti-ovarian cancer CD8(+) T cells by dendritic cells loaded with nanoparticle encapsulated tumor antigen. Am J Reprod Immunol (2011) 0.86
Tumor lysate-loaded biodegradable microparticles as cancer vaccines. Expert Rev Vaccines (2014) 0.79
An antibiotic-responsive mouse model of fulminant ulcerative colitis. PLoS Med (2008) 2.50
Leukocyte-inspired biodegradable particles that selectively and avidly adhere to inflamed endothelium in vitro and in vivo. Proc Natl Acad Sci U S A (2003) 1.48
Characterization of the transgene expression generated by branched and linear polyethylenimine-plasmid DNA nanoparticles in vitro and after intraperitoneal injection in vivo. J Control Release (2008) 1.42
Optimization of yield in magnetic cell separations using nickel nanowires of different lengths. Biotechnol Prog (2005) 1.37
Innovative strategies for co-delivering antigens and CpG oligonucleotides. Adv Drug Deliv Rev (2009) 1.28
Potent antigen-specific immune responses stimulated by codelivery of CpG ODN and antigens in degradable microparticles. J Immunother (2007) 1.24
Nanoparticle delivery systems in cancer vaccines. Pharm Res (2010) 1.20
TRAIL gene therapy: from preclinical development to clinical application. Curr Gene Ther (2009) 1.13
Formulating poly(lactide-co-glycolide) particles for plasmid DNA delivery. J Pharm Sci (2008) 1.11
The enhancement of bone regeneration by gene activated matrix encoding for platelet derived growth factor. Biomaterials (2013) 1.10
Biodegradable particles as vaccine delivery systems: size matters. AAPS J (2012) 1.09
Comparative study of poly (lactic-co-glycolic acid)-poly ethyleneimine-plasmid DNA microparticles prepared using double emulsion methods. J Microencapsul (2008) 1.02
Fabrication, characterization and in vitro evaluation of poly(D,L-lactide-co-glycolide) microparticles loaded with polyamidoamine-plasmid DNA dendriplexes for applications in nonviral gene delivery. J Pharm Sci (2010) 1.02
A comparative study of the antigen-specific immune response induced by co-delivery of CpG ODN and antigen using fusion molecules or biodegradable microparticles. J Pharm Sci (2007) 1.01
Synthesis and characterization of mannosylated pegylated polyethylenimine as a carrier for siRNA. Int J Pharm (2011) 1.01
Prostate cancer vaccines: Update on clinical development. Oncoimmunology (2013) 0.98
Conjugation of polyamidoamine dendrimers on biodegradable microparticles for nonviral gene delivery. Bioconjug Chem (2007) 0.97
Diet-induced obesity alters dendritic cell function in the presence and absence of tumor growth. J Immunol (2012) 0.97
Effect of crystal size and surface functionalization on the cytotoxicity of silicalite-1 nanoparticles. Chem Res Toxicol (2009) 0.96
Pulsatile release of biomolecules from polydimethylsiloxane (PDMS) chips with hydrolytically degradable seals. J Control Release (2008) 0.95
Development of a poly (lactic-co-glycolic acid) particle vaccine to protect against house dust mite induced allergy. AAPS J (2014) 0.91
Optimized dextran-polyethylenimine conjugates are efficient non-viral vectors with reduced cytotoxicity when used in serum containing environments. Int J Pharm (2011) 0.90
Immune stimulatory antigen loaded particles combined with depletion of regulatory T-cells induce potent tumor specific immunity in a mouse model of melanoma. Cancer Immunol Immunother (2008) 0.90
CD4-directed peptide vaccination augments an antitumor response, but efficacy is limited by the number of CD8+ T cell precursors. J Immunol (2004) 0.88
Rational design, fabrication, characterization and in vitro testing of biodegradable microparticles that generate targeted and sustained transgene expression in HepG2 liver cells. J Drug Target (2010) 0.87
The combination of a low-dose chemotherapeutic agent, 5-fluorouracil, and an adenoviral tumor vaccine has a synergistic benefit on survival in a tumor model system. PLoS One (2013) 0.85
CpG oligonucleotides as immunotherapeutic adjuvants: innovative applications and delivery strategies. Adv Drug Deliv Rev (2009) 0.84
Characterizing the antitumor response in mice treated with antigen-loaded polyanhydride microparticles. Acta Biomater (2012) 0.84
Effects of glucocorticoid receptor small interfering RNA delivered using poly lactic-co-glycolic acid microparticles on proliferation and differentiation capabilities of human mesenchymal stromal cells. Tissue Eng Part A (2012) 0.84
Applying biodegradable particles to enhance cancer vaccine efficacy. Immunol Res (2014) 0.84
Chitosan coating of copper nanoparticles reduces in vitro toxicity and increases inflammation in the lung. Nanotechnology (2013) 0.84
Proposed mechanisms of action for prostate cancer vaccines. Nat Rev Urol (2013) 0.82
Biodegradable microparticles loaded with doxorubicin and CpG ODN for in situ immunization against cancer. AAPS J (2014) 0.82
CpG-mediated modulation of MDSC contributes to the efficacy of Ad5-TRAIL therapy against renal cell carcinoma. Cancer Immunol Immunother (2014) 0.82
Rapid localized cell trapping on biodegradable polymers using cell surface derivatization and microfluidic networking. Biomaterials (2005) 0.82
Intracellular release of 17-β estradiol from cationic polyamidoamine dendrimer surface-modified poly (lactic-co-glycolic acid) microparticles improves osteogenic differentiation of human mesenchymal stromal cells. Tissue Eng Part C Methods (2010) 0.80
T cell-mediated delay of spontaneous mammary tumor onset: increased efficacy with in vivo versus in vitro activation. J Immunol (2005) 0.79
Effects of obesity on immune responses to renal tumors. Immunol Res (2014) 0.79
New class of biodegradable polymers formed from reactions of an inorganic functional group. Macromolecules (2012) 0.79
Spatial control over cell attachment by partial solvent entrapment of poly lysine in microfluidic channels. Int J Nanomedicine (2006) 0.79
Tumor lysate-loaded biodegradable microparticles as cancer vaccines. Expert Rev Vaccines (2014) 0.79
Efficacy of polymeric encapsulated C5a peptidase-based group B streptococcus vaccines in a murine model. Am J Obstet Gynecol (2011) 0.79
The absence of CpG in plasmid DNA-chitosan polyplexes enhances transfection efficiencies and reduces inflammatory responses in murine lungs. Mol Pharm (2014) 0.78
Silicalite nanoparticles that promote transgene expression. Nanotechnology (2008) 0.78
Biotinylated biodegradable nanotemplated hydrogel networks for cell interactive applications. Biomacromolecules (2008) 0.78
Manipulation of Cell Physiology Enables Gene Silencing in Well-differentiated Airway Epithelia. Mol Ther Nucleic Acids (2012) 0.78
Microparticles prepared from sulfenamide-based polymers. J Microencapsul (2013) 0.78
Antigen-coated poly α-hydroxy acid based microparticles for heterologous prime-boost adenovirus based vaccinations. Biomaterials (2013) 0.78
Mitochondria-targeting particles. Nanomedicine (Lond) (2014) 0.77
Chitosan is a surprising negative modulator of cytotoxic CD8+ T cell responses elicited by adenovirus cancer vaccines. Mol Pharm (2011) 0.77
Glucocorticoid receptor antagonist and siRNA prevent senescence of human bone marrow mesenchymal stromal cells in vitro. Cell Tissue Res (2013) 0.77
A promising CpG adjuvant-loaded nanoparticle-based vaccine for treatment of dust mite allergies. Immunotherapy (2014) 0.77
Production of antigen-loaded biodegradable nanoparticles and uptake by dendritic cells. Methods Mol Biol (2014) 0.76
Recent progress in non-viral nucleic acids delivery. Int J Pharm (2011) 0.76
NLRC4 suppresses melanoma tumor progression independently of inflammasome activation. J Clin Invest (2016) 0.76
Synthesis of the first poly(diaminosulfide)s and an investigation of their applications as drug delivery vehicles. Macromolecules (2012) 0.76
Immunostimulatory sutures that treat local disease recurrence following primary tumor resection. Biomed Mater (2011) 0.76
Gene-Activated Titanium Surfaces Promote In Vitro Osteogenesis. Int J Oral Maxillofac Implants (2016) 0.76
Multifunctional nanorods for biomedical applications. Pharm Res (2007) 0.76
Correction: MicroRNA-200c Represses IL-6, IL-8, and CCL-5 Expression and Enhances Osteogenic Differentiation. PLoS One (2016) 0.75
A Pilot Study Evaluating Combinatorial and Simultaneous Delivery of Polyethylenimine-Plasmid DNA Complexes Encoding for VEGF and PDGF for Bone Regeneration in Calvarial Bone Defects. Curr Pharm Biotechnol (2015) 0.75
Poly(galactaramidoamine) is an efficient cationic polymeric non-viral vector with low cytotoxicity for transfecting human embryonic kidney (HEK293) and murine macrophage (RAW264.7) cells. Pharm Dev Technol (2012) 0.75
Effect of combined locally delivered growth factors and systemic sildenafil citrate on microrecanalization in biodegradable conduit for vas deferens reconstruction. Urology (2012) 0.75
Recent progress on the development of gene-activated scaffolds encoding PDGF for enhanced bone regeneration. Regen Med (2014) 0.75